Media Contact: Ron Rogers (801) 584-3065 firstname.lastname@example.org
Investor Contact: Scott Gleason (801) 584-1143 email@example.com
Myriad RBM’s TruCulture® and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut PasteurSALT LAKE CITY, Utah, September 7, 2016 – Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN) a global leader in personalized medicine, announced today that researchers from the Institut Pasteur have published new landmark research from the Milieu Interieur Project relating to the ability to perform standardized transcriptome profiling based upon a variety of immune stimuli in the August issue of Cell Reports. The study looked at the expression levels of different genes in 25 subjects following TruCulture incubation with twenty clinically relevant immune system stimulants. The research demonstrated that expression levels from as few as 44 of the 572 genes tested could segregate responses from the various stimuli and reveal variations in immune response.
“We are excited by the results of this study which demonstrated that a relatively small subset of gene expression targets could explain the variability in immune response to different immune stimuli seen among patients,” said Matthew Albert, co-coordinator of Milieu Interieur and director of the Immunobiology of Dendritic Cells Unit at the Institut Pasteur. “The ability of TruCulture to perform this analysis in an ex-vivo environment is truly unique making it an invaluable tool for assessing potential biomarkers relevant to immune response in patients.”To perform the study, the researchers at the Institute Pasteur utilized Myriad RBM’s TruCulture technology which is a proprietary blood collection and culturing system that allows researchers to perform ex-vivo immune system analysis. Unlike the current laboratory-based methods, TruCulture is deployed at the site of collection and therefore avoids variability from shipping and complex processing as well as the expense of a cell culture facility and staff.
“We are increasingly excited around the prospects for TruCulture both for use in pharmaceutical research as well as for potential future diagnostic products,” said Ralph McDade, president of Myriad RBM. “We are actively pursuing several research collaborations to develop TruCulture as a novel diagnostic in cancer immunotherapy, autoimmune disorders, mental illness and vaccine response.”This research builds upon earlier work at the Institut Pasteur that looked at the ability of TruCulture to accurately and reproducibly measure protein based cytokine responses in patient samples relative to different immune stimuli. The approaches and learnings from this study and previous studies will now be utilized in over 1,000 healthy donors with the Milieu Interieur cohort that will evaluate how different factors such as age, gender, environment, lifestyle, and genetics contribute to variable immune responses.